The National Organization for Rare Disorders (NORD)

Database Subscriptions

Many libraries, schools, universities, and hospitals subscribe to NORD’s Rare Disease Database for unlimited access to reports on more than 1,200 diseases.

Index of Rare Diseases

This is the list of diseases currently covered in the Rare Disease Database.

Rare Disease Database

Search this database for reports on more than 1,200 diseases.

View sample report

Index of Organizations

This is the list of organizations in NORD’s Organizational Database.

Organizational Database

Read about more than 2,000 patient organizations and other sources of help.

NORD's
Washington Office

Check here to read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.

 

News Briefs

NF1 Research: When a Good Gene Goes Bad

In a major research advance, scientists at the University of Texas Southwestern Medical Center in Dallas have identified the cells that cause tumors to form in neurofibromatosis type 1 when a "good gene" goes bad. Their work may ultimately shed light on the way in which many common cancers begin.

Luis Parada, a molecular biologist, and colleagues at UT Southwestern and in France, developed genetically engineered mice that had one good and one bad copy of the NF1 gene - the gene linked to the disease. They were able to show that Schwann cells, which insulate nerve fibers, are the cells that start a tumor when the good copy of the gene mutates.

The neurofibromatoses are genetic disorders that cause many benign tumors, which may eventually become malignant, to grow along various types of nerves. The disease also can affect the bones and skin, and sometimes includes developmental abnormalities such as learning disabilities. It's been classified into two types: NF1 and NF2. In NF2, in addition to basic neurofibromatosis symptoms, people experience hearing loss.

In addition to the initial finding, the research showed that mast cells, which are immune system cells, assist in the formation of tumors. Tumors formed only when the mast cells also had one bad copy of the NF1 gene. This finding is important because it sheds light on the role of non-cancerous cells in forming tumors. That may ultimately help to explain why, for instance, some people known to inherit cancer-causing mutations don't develop the disease.


You may reprint NORD's News Briefs in your newsletter or other publication as long as credit is given to The National Organization for Rare Disorders (NORD), with reference to our web site: www.rarediseases.org.

Over 1200 Disease Reports
Not a Subscriber yet?
                    Details Here

Enter your name and e-mail address if you would like to receive "News Blasts" from NORD






ABOUT | CONTACT NORD

Since 1983, working toward the prevention, treatment, and cure of rare “orphan” diseases.

Previous News Briefs

ICORD 2008

FDA and European Union Adopt Shared Form

NORD Representatives Address Congress

CETT Increases Access to Genetic Tests

NORD Honors Innovators at 2007 Tribute Banquet

Stay connected!

If you liked these News Briefs, you’ll love our free e-mail News Blasts. You’ll receive breaking news affecting the rare-disease community directly in your inbox if you enter your e-mail address in the box at the top of this page.

ABOUT NORD .|. CONTACT NORD .|. MEMBERSHIP .|. PRIVACY POLICY .|. DISCLAIMER .|. HOME
©2009 NORD - National Organization for Rare Disorders, Inc. All rights reserved.

Last modified Monday, June 02, 2008